EVFM Insider Trading Activity and SEC Form 4 Filings
EVFM insider trading summary
No open-market insider purchases or sales of Evofem Biosciences, Inc. (EVFM) have been reported on SEC Form 4 in the past 12 months.
Latest EVFM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 12, 2024 | Yan Zhang | CFO | Sell | $4 (104 @ $0.04) |
| Dec 21, 2023 | Kim P. Kamdar | Director | Sell | $6 (10 @ $0.62) |
| May 27, 2022 | Saundra L Pelletier | Chief Executive Officer | Buy | $50K (141,000 @ $0.35) |
| Dec 20, 2021 | Alexander A Fitzpatrick | General Counsel and Secretary | Buy | $10K (25,000 @ $0.39) |
| Dec 20, 2021 | Saundra L Pelletier | Chief Executive Officer | Buy | $51K (135,000 @ $0.38) |
| Dec 20, 2021 | Justin J. File | Chief Financial Officer | Buy | $15K (40,594 @ $0.37) |
| Jun 18, 2021 | Kim P. Kamdar | Director | Buy | $12K (10,000 @ $1.17) |
| Jun 14, 2021 | Anthony Stephen O'Brien | Director | Buy | $11K (8,140 @ $1.31) |
| Jun 11, 2021 | Russell Barrans | Chief Commercial Officer | Buy | $21K (18,180 @ $1.14) |
| Jun 11, 2021 | Lisa Dale Rarick | Director | Buy | $6K (5,000 @ $1.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.